Iptcaopan 200 mg
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atypical Hemolytic Uremic Syndrome
Conditions
Atypical Hemolytic Uremic Syndrome
Trial Timeline
May 8, 2024 → Jan 3, 2033
NCT ID
NCT05795140About Iptcaopan 200 mg
Iptcaopan 200 mg is a phase 3 stage product being developed by Novartis for Atypical Hemolytic Uremic Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05795140. Target conditions include Atypical Hemolytic Uremic Syndrome.
What happened to similar drugs?
1 of 7 similar drugs in Atypical Hemolytic Uremic Syndrome were approved
Approved (1) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05795140 | Phase 3 | Recruiting |
Competing Products
18 competing products in Atypical Hemolytic Uremic Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 44 |
| Crovalimab | Chugai Pharmaceutical | Phase 3 | 44 |
| Duloxetine | Eli Lilly | Approved | 43 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 40 |
| Baricitinib | Eli Lilly | Pre-clinical | 26 |
| Ravulizumab | AstraZeneca | Pre-clinical | 33 |
| Eculizumab | AstraZeneca | Phase 3 | 40 |
| Iptacopan | Novartis | Phase 3 | 44 |
| Iptacopan | Novartis | Phase 3 | 47 |
| Ropeginterferon Alfa-2B | PharmaEssentia | Phase 2 | 42 |
| CCX168 | Amgen | Phase 2 | 27 |
| Tazemetostat + Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 1/2 | 39 |
| Cemdisiran | Alnylam Pharmaceuticals | Phase 2 | 24 |
| cemdisiran + Placebos | Alnylam Pharmaceuticals | Phase 2 | 24 |
| Axatilimab + Azacitidine | Incyte | Phase 1/2 | 36 |
| Gemcitabine + Paxalisib | Pacific Biosciences | Phase 2 | 32 |
| Apatinib Mesylate | Brain Biotech | Pre-clinical | 23 |
| azurin-derived cell-penetrating peptide p28 | Brain Biotech | Phase 1 | 19 |